# OnCo record tislelizumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tislelizumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tislelizumab" ;
  schema:name "Tislelizumab"@en ;
  schema:description "A Chinese-developed PD-1 blocker, engineered to avoid a side-channel that may blunt other PD-1 drugs, now approved in the US and EU for oesophageal and stomach cancer."@en ;
  schema:url <https://onco.cc/drugs/tislelizumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tislelizumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q28209583> ;
  schema:citation <https://www.onclive.com/view/fda-approves-first-line-tislelizumab-plus-chemotherapy-for-unresectable-or-metastatic-escc> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-PD-1)" ;
  schema:alternateName "Tevimbra" ;
  onco:approval "China 2019: Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal", "US 2024: Second-line ESCC after chemotherapy; first-line HER2-negative gastric/GEJ with chemotherapy (PD-L1 ≥1)", "US 2025: First-line ESCC, PD-L1 ≥1%, with platinum chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/beone/> ;
  onco:terms <https://onco.cc/terms/irae/>, <https://onco.cc/terms/fc-effector/> ;
  onco:trials <https://onco.cc/trials/rationale-306/>, <https://onco.cc/trials/herizon-gea-01/>, <https://onco.cc/trials/rationale-302/>, <https://onco.cc/trials/nct07502300/>, <https://onco.cc/trials/nct04379635/>, <https://onco.cc/trials/nct07170995/>, <https://onco.cc/trials/nct05840016/>, <https://onco.cc/trials/nct06030258/>, <https://onco.cc/trials/nct05651022/>, <https://onco.cc/trials/nct05431270/>, <https://onco.cc/trials/nct05609370/>, <https://onco.cc/trials/nct05635708/>, <https://onco.cc/trials/nct05661955/>, <https://onco.cc/trials/nct07244705/>, <https://onco.cc/trials/nct06427941/>, <https://onco.cc/trials/nct05632939/>, <https://onco.cc/trials/nct07700667/>, <https://onco.cc/trials/nct07554521/>, <https://onco.cc/trials/nct07331155/>, <https://onco.cc/trials/nct06745908/>, <https://onco.cc/trials/nct04699188/>, <https://onco.cc/trials/nct07315750/>, <https://onco.cc/trials/nct04170283/>, <https://onco.cc/trials/nct03967977/>, <https://onco.cc/trials/nct07554456/>, <https://onco.cc/trials/nct06499350/>, <https://onco.cc/trials/nct07390383/>, <https://onco.cc/trials/nct06825494/>, <https://onco.cc/trials/nct07019675/>, <https://onco.cc/trials/nct07669415/>, <https://onco.cc/trials/nct03736889/> .